anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a monoclonal antibody for identifying N6 subtype avian influenza virus neuraminidase protein and application thereof. The monoclonal antibody is secreted and generated by a hybridoma cell strain 3H7 with the preservation number of CGMCC No. 18900. Experiments prove that the monoclonal antibody 3H7 obtained by the invention can be specifically combined with the N6 subtype avian influenza virus, and can be combined with 15 strains of N6 subtype avian influenza viruses with different evolutionary branches, which shows that the 3H7 has good broad spectrum. The invention establishes an ELISA detection kit for N6 subtype avian influenza virus neuraminidase protein antibody blocking and a detection method thereof by utilizing the better broad spectrum and specificity of the monoclonal antibody. Experiments prove that the method has high sensitivity and good repeatability, can be used for detecting the level of N6 subtype avian influenza virus neuraminidase protein antibody in clinical serum samples, and has good development prospect.
Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years.
Long‑term studies in animals have not been performed to evaluate carcinogenic potential. 

AUGMENTIN (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. AUGMENTIN was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. AUGMENTIN was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays.

AUGMENTIN (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats. Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area.
BACKGROUND: Neurogenic overactive bladder (OAB) is a distressing condition in stroke. Existing neurogenic OAB management is expensive, unstandardized regimens, or invasive. Evaluating the effectiveness of repetitive transcranial magnetic stimulation (rTMS) remains crucial. We aimed to (1) compare the effectiveness of active-rTMS with sham-rTMS on neurogenic OAB symptoms, (2) analyze whether rTMS is cost-effective, and (3) explore the rTMS's experiences on participants' symptoms.
METHODS: This is a randomized, sham-controlled, double-blinded trial with embedded qualitative and cost-effectiveness studies. A total of 110 stroke survivors with neurogenic OAB symptoms were screened for eligibility; 60 participants were eligible for inclusion and were randomly assigned to either the active (n = 30) or sham-rTMS (n = 30) groups using a computer-generated randomization schedule. The active-rTMS group received low-frequency rTMS of 1200 pulses per session lasting 20 min thrice weekly to pelvic floor muscle representation at the contralesional primary motor cortex. The sham-rTMS group received low-frequency stimulation at a 20 % resting motor threshold using the same coil as the active-rTMS but was configured to reduce the TMS-induced electrical fields significantly. The primary and secondary outcome measures were assessed at baseline, post-intervention (week 4) and follow-up (week 8). The analysis of covariance (ANCOVA) analysis compared changes in the study groups. Quality-adjusted life-years (QALY) were measured to evaluate the cost-effectiveness while EQ-5D-5L estimated QALY changes. Additionally, the focus group discussion data were thematically analyzed.
CONCLUSIONS: The findings from this rTMS intervention study will be useful in alleviating neurogenic OAB symptoms and enhancing patient satisfaction in a cost-effective way.
PURPOSE:To obtain a healthy and beauty promoter, etc., having safe and excellent SOD action (action to effectively remove O2-considered as toxic to the living body and action on prevention, etc., of diseases) by using rice brans and soybeans as a raw material. CONSTITUTION:This healthy and beauty promoter having SOD action is characterized by inoculating Bacillus subtilis into a culture medium containing rice brans and soybeans, culturing the Bacillus subtilis, filtering the resultant culture, producing a fermentation liquor and blending a concentrate (e.g. 40-50wt.% concentration) of the resultant fermentation liquor with a green tea extract essence (e.g. 40-50wt.% concentration) in an amount of 1-50 pts.wt. expressed in terms of an evaporation residue based on 100 pts.wt. evaporation residue of the fermentation liquor. A flavonoid can be contained in the fermented liquor and the green tea extract essence can contain phytic acid or its salt. The evaporation residue (solid substance) can be used in place of the respective solutions. This promoter can be utilized as a blood pressure suppressor and a constipation improver.
Mechanisms nourish stem cells for organ regeneration and prevent alcohol related diseases such as Fetal Alcohol Syndrome (FAS) and Liver Sclerosis. These stem cell nutrients have been found to positively affect the skin, liver, brain neurons, pancreas, and the GI tract. Cholesterol supplementation prevents fetal alcohol spectrum defects (FASD) in alcohol-exposed zebra fish embryos. Using the zebra fish model, alcohol was found to interfere with embryonic development by disrupting cholesterol-dependent activation of a critical signaling molecule, sonic hedgehog (Shh). Cholesterol supplementation of the alcohol-exposed embryos restored the functionality of the molecular pathway and prevented development of FASD-like defects. Novel biomarkers were identified for diagnosing alcohol related diseases by lipid chemical analysis and Raman Spectroscope.
Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle using a combination of therapies. The method may include the introduction of structurally reinforcing agents. In other embodiments, agents may be introduced into a ventricle to increase compliance of the ventricle. The prevention of remodeling may include the prevention of thinning of the ventricular infarct zone. Another embodiment includes the reversing or prevention of ventricular remodeling with electro-stimulatory therapy. The unloading of the stressed myocardium over time effects reversal of undesirable ventricular remodeling. These therapies may be combined with structurally reinforcing therapies. In other embodiments, the structurally reinforcing component may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.
Patients will be prospectively enrolled whilst attending for elective coronary CT (computed tomography) angiography including a coronary calcium score, at the Royal Surrey County Hospital. Data regarding demographic and clinical characteristics of patients will be collected. Peripheral venous blood sampling will take place on this occasion. Coronary artery calcification scores will be estimated by a Radiologist using default software. Patients eligible for the bone metabolism substudy will be required to attend the University of Surrey for peripheral Quantitative Computed Tomography (pQCT) of bone mineral composition of the radius. In the intervening period we will ask them to complete a 4-day food diary and wear a UV dosimeter, the latter to assess typical UV exposure, for one week.
Lewy Body Dementia (LBD) is the second most common type of dementia next to Alzheimer's Dementia, but many patients with this disease go undiagnosed or misdiagnosed. A clinical feature of this disease is sensitivity to certain medications such as antipsychotics and benzodiazepines, which can potentially worsen their symptoms and/or increase the risk of death. With neuropsychiatric symptoms being the leading cause for acute hospital visits in patients with LBD, over a third of patients receive antipsychotics in the hospital, a third end up needing a higher level of care after discharge, and a third of patients with dementia end up dying within the first year after an ED visit. Currently, there is not enough data for the best pharmacologic management of acute behavioral disturbances in older patients, but we do have international LBD guidelines that we can start to implement.

Since the ED is a place with high usage of antipsychotics/benzodiazepines, the purpose of this study is to measure the proportion of older patients who are receiving these medications during an ED visit. Of the older patients who received these medications, this study will measure which fraction of the patients might have an underlying diagnosis of dementia or movement disorder. The goal is to implement new hospital guidelines to help reduce the usage of these medications in older patients, thus the study will measure the proportion of older patients receiving these medications before and after the new hospital guidelines are implemented. The study will also directly measure the treatment knowledge of providers working in the ED by having them answer a clinical scenario/patient case question before and after the guidelines are presented to them. The ultimate goal of this study is to help improve patient outcomes in older people who visit the hospital by avoiding medications that could be potentially harmful to their health.
LncRNAs and miRNAs, being the master regulators of gene expression, are crucial functional mediators in cancer. Our study unveils the critical regulatory role of the metastatic long non-coding RNA LINC00273 as the master regulator of oncogenes involved in cancer metastasis, stemness, and chemoresistance via its miRNA sponging mechanism. M2 (a salt of bis-Schiff base) mediated G quadruplex (G4) stabilization at the LINC00273 gene promoter remarkably inhibits LINC00273 transcription. Therefore, low-level LINC00273 transcripts are unable to efficiently sponge the miRNAs, which subsequently become available to bind and downregulate their target oncogenes. We have observed significantly different global transcriptomic scenarios in LINC00273 upregulated and downregulated circumstances in MDA-MB-231 triple-negative breast cancer model. Additionally, we have found the G4 sequence in the LINC00273 RNA to play a critical role in miRNA sequestration. miRNAs (miR-6789-5p, miR200b, miR-125b-5p, miR-4268, miR3978) have base pairing complementarity within the G4 region of LINC00273 RNA and the 3'-UTR (untranslated region) of MAPK12, TGF-β1, and SIX-1 transcripts. We have reported TGF-β1, SIX-1, and MAPK12 to be the direct downstream targets of LINC00273. The correlation between abnormal expression of lncRNA LINC00273 and TNBC aggressiveness strongly evidenced in our study shall accelerate the development of lncRNA-based anti-metastatic therapeutics.
Provided is a microneedle patch comprising a substrate part and multiple needle parts that protrude from the substrate part. The substrate part consists of diffusion-proof layer and base, and each needle part consists of needle tip, diffusion-proof layer and base. The diffusion-proof layer of each needle part is formed between the needle tip and the base of corresponding needle part. The diffusion-proof layer of substrate part and the diffusion-proof layer of needle part are one-piece structure, and so are the base of substrate part and the base of needle part. The needle layer comprises HA, PVP and a first carbohydrate, the diffusion-proof layer comprises a second carbohydrate, PVA and HP-[beta]-CD, and the base comprises a third carbohydrate, PVA and HP-[beta]-CD. The diffusion-proof layer of the microneedle patch has diffusion-proof effect which can prevent the active ingredients from diffusing to the base, limit the active ingredients to the needle tip and control the carrying quantity thereof.
PURPOSE: The National Congenital Anomaly and Rare Disease Registration Service (NCARDRS), part of National Disease Registration Service in National Health Service England, quality assures, curates and analyses individual data on the pregnancies, fetuses, babies, children and adults with congenital anomalies and rare diseases across England. The congenital anomaly (CA) register provides a resource for patients and their families, clinicians, researchers and public health professionals in furthering the understanding of CAs.
PARTICIPANTS: NCARDRS registers CAs occurring in babies born alive and stillborn, fetal losses and terminations in England. NCARDRS collects data from secondary and tertiary healthcare providers, private providers and laboratories covering fetal medicine, maternity or paediatric services. Data describe the pregnancy, mother, baby and anomaly. Established in 2015, NCARDRS expanded CA registration coverage from 22% of total births in England in 2015 to national coverage, which was achieved in 2018. Prior to 2015, data collection was performed independently by regional registers in England; these data are also held by NCARDRS.
FINDINGS TO DATE: NCARDRS registers approximately 21 000 babies with CAs per year with surveillance covering around 600 000 total births, the largest birth coverage for a CA register globally. Data on prevalence, risk factors and survival for children with CAs are available. Data have been used in several peer-reviewed publications. Birth prevalence statistics, including public health indicators such as the association with maternal age, infant and perinatal mortality, are published annually. NCARDRS supports clinical audit for screening programmes and service evaluation.
FUTURE PLANS: NCARDRS provides a valuable resource for the understanding of the epidemiology, surveillance, prevention and treatment of CAs. Currently, approximately 21 000 new registrations of babies or fetuses with suspected or confirmed CAs are added each year. Identifiers are collected, enabling linkage to routinely collected healthcare and population statistics, further enhancing the value of the data.
Two weekly doses of pre-operative cetuximab during the interval between diagnostic HNSCC biopsy and surgery (\~14 days), ensuring that no delay in standard of care (SOC) will occur. For dose #1, participants will receive cetuximab 400 mg/m2 via intravenous infusion over 2 hours (maximum infusion rate 10 mg/min) as per the standard of care loading regimen for cetuximab monotherapy. For dose #2, participants will receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
PURPOSE: An organic germanium compound and a salt thereof are provided to easily absorb into human body and to ensure efficiency without toxicity. CONSTITUTION: An organic germanium compound is denoted by chemical formula 1. A pharmaceutical composition for preventing cancer or inflammatory diseases or enhancing immunity contains the germanium compound or salt thereof as an active ingredient. The cancer is gastric cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, bladder cancer, brain cancer or skin cancer. The inflammatory diseases are hepatitis, atopic dermatitis or psoriasis. A cosmetic composition for improving skin condition contains the organic germanium compound or salt thereof as an active ingredient.
The present invention relates to a multiphase cleansing bar having a plurality of phases of cleansing material. Adjacent phases preferably have different concentration levels of benefit components respectively and all the phases individually preferably have a substantially similar cleansing base consisting of a syndet base, a soap base, or mixtures thereof. These benefit components are emollients, moisturizers, nutrients, anti-aging materials etc. Segregation of the benefit rich component is expected to result in improved deposition of the benefit components on the skin during the product application, which improves the moisture barrier properties of the skin. Chemical and Theological compatibility between the phases is maximized and recycling of the product during production is facilitated with the use of a uniform cleansing base. Methods of producing the inventive bar by extruding and melt casting are also disclosed.
The present invention relates to a novel co-administration EGFR antibody used in preventing or treating cancer. The antibody of the present invention is specifically coupled with EGFR overexpressed in cancer cells (in particular, colon cancer), and is coupled with an epitope which is different from cetuximab. Compared to CDR sequences of conventional EGFR target antibodies, the antibody of the present invention has very low homogeneity, and thus the sequence thereof is unique. When the antibody of the present invention is co-administrated with cetuximab, cancer cells are killed through a remarkably improved cancer cell killing function. Thus, the antibody of the present invention is very effective in preventing or treating cancer (in particular, colon cancer). The excellence of a co-administration effect of the antibody of the present invention, without wishing to be bound by theory, is determined by considering that the antibody of the present invention is coupled with an epitope on EGFR which is different from cetuximab to control EGFR cooperatively with cetuximab.
BACKGROUND: Neoadjuvant chemoradiation and chemotherapy are recommended for the treatment of nonmetastatic esophageal cancer. The benefit of neoadjuvant treatment is mostly limited to patients who exhibit pathologic complete response (pCR). Existing estimates of pCR rates among patients receiving neoadjuvant therapy have not been synthesized and lack precision.
METHODS: We conducted an independently funded systematic review and meta-analysis (PROSPERO CRD42023397402) of pCR rates among patients diagnosed with esophageal cancer treated with neoadjuvant chemo(radiation). Studies were identified from Medline, EMBASE, and CENTRAL database searches. Eligible studies included trials published from 1992 to 2022 that focused on nonmetastatic esophageal cancer, including the gastroesophageal junction. Histology-specific pooled pCR prevalence was determined using the Freeman-Tukey transformation and a random effects model.
RESULTS: After eligibility assessment, 84 studies with 6451 patients were included. The pooled prevalence of pCR after neoadjuvant chemotherapy in squamous cell carcinomas was 9% (95% CI: 6%-14%), ranging from 0% to 32%. The pooled prevalence of pCR after neoadjuvant chemoradiation in squamous cell carcinomas was 32% (95% CI: 26%-39%), ranging from 8% to 66%. For adenocarcinoma, the pooled prevalence of pCR was 6% (95% CI: 1%-12%) after neoadjuvant chemotherapy, and 22% (18%-26%) after neoadjuvant chemoradiation.
CONCLUSIONS: Under one-third of patients with esophageal cancer who receive neoadjuvant chemo(radiation) experience pCR. Patients diagnosed with squamous cell carcinomas had higher rates of pCR than those with adenocarcinomas. As pCR represents an increasingly utilized endpoint in neoadjuvant trials, these estimates of pooled pCR rates may serve as an important benchmark for future trial design.
OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
Patients receive bortezomib 1.3 mg/m\^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
Fragmentation patterns observed in plasma DNA reflect chromatin accessibility in contributing cells. Since DNA shed from cancer cells and blood cells may differ in fragmentation patterns, we investigated whether analysis of genomic positioning and nucleotide sequence at fragment ends can reveal the presence of tumor DNA in blood and aid cancer diagnostics. Whole genome sequencing data from >2700 plasma DNA samples including healthy individuals and patients with 11 different cancer types were analyzed. Higher fractions of fragments with aberrantly positioned ends were observed in patients with cancer, driven by contribution of tumor DNA into plasma. Genome wide analysis of fragment ends using machine learning showed overall area under the receiver operative characteristic curve of 0.96 for detection of cancer. These findings remained robust with as few as 1 million fragments analyzed per sample, indicating that analysis of fragment ends is a cost-effective and accessible approach for cancer detection and monitoring.
PURPOSE: To obtain healthy beverage containing collagen and extract of leaf of Eucommia Ulmoides Olive. as active ingredients, promoting collagen metabolism and useful for relieving pain of knee and improving chapped skin, etc. CONSTITUTION: This healthy beverage is obtained by adding collagen powder and extract of the leaf of Eucommia Ulmoides Oliv. to purified water, specifically, putting, e.g. 700g leaf of Eucommia Ulmoides Oliv. into 1000ml purified water and concentrating the solution to 300ml to afford an extract of leaf of Eucommia Ulmoides Oliv. and adding the extract of leaf of Eucommia Ulmoides Oliv. to purified water, heating the mixture to 50-60 deg.C, gradually adding collagen powder thereto and properly heating the mixture to about 95 deg.C and adding sweetener, flavor and antiseptic thereto. Collagen in an amount of 100-150g and extract of leaf of Eucommia Ulmoides Oliv. in an amount of 30-100ml are preferably added based on 500ml beverage.
The expert working group will consist of at least 5 and up to 12 people with LLA actively receiving prosthetic care, and at least 5 and up to 12 prosthetic care providers with greater than 5 years of experience. Individuals will be invited to join the expert working group based on expertise, and representation of key stakeholders relevant to the prosthetic design process.
Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.